Dr. Yu on Trials of Moderate Hypofractionation in Prostate Cancer

James B. Yu, MD
Published: Tuesday, Apr 11, 2017



James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses current data in support of using moderate hypofractionation in prostate cancer.

The results of the RTOG-0415 trial, presented by W. Robert Lee, MD, during the 2016 Genitourinary Cancers Symposium, showed that hypofractionation was equivalent and noninferior to the control. The PROFIT study showed similar results.

Additionally, Yu says that there is a chance for a slight rise in toxicities, which is attributed to the radiation being given faster.
 


James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses current data in support of using moderate hypofractionation in prostate cancer.

The results of the RTOG-0415 trial, presented by W. Robert Lee, MD, during the 2016 Genitourinary Cancers Symposium, showed that hypofractionation was equivalent and noninferior to the control. The PROFIT study showed similar results.

Additionally, Yu says that there is a chance for a slight rise in toxicities, which is attributed to the radiation being given faster.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x